Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 17, 2021

Novartis’ prostate cancer drug secures FDA breakthrough designation

Novartis has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for Lu-PSMA-617 to treat metastatic castration-resistant prostate cancer (mCRPC).

Novartis is developing new radioligand therapy for metastatic prostate cancer. Credit: Novartis AG.